# EDGAR Filing Document

**Accession Number:** 0001681087
**File Stem:** 0001140361-23-008899
**Filing Date:** 2023-2
**Character Count:** 5023
**Document Hash:** 821ecd212689b39dd6a4c439c4509b6a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-008899.hdr.sgml**: 20230227

**ACCESSION NUMBER**: 0001140361-23-008899

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230223

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230227

**DATE AS OF CHANGE**: 20230227

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVROBIO, Inc.
- **CENTRAL INDEX KEY:** 0001681087
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 810710585
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38537
- **FILM NUMBER:** 23675675

**BUSINESS ADDRESS:**
- **STREET 1:** 100 TECHNOLOGY SQUARE
- **STREET 2:** 6TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617.914.8420

**MAIL ADDRESS:**
- **STREET 1:** 100 TECHNOLOGY SQUARE
- **STREET 2:** 6TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AvroBio, Inc.
- **DATE OF NAME CHANGE:** 20160729

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): February 23, 2023

------

## AVROBIO, INC.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38537** | **81-0710585** |
| **(State or other jurisdiction of incorporation)** | **(Commission File Number)** | **(I.R.S. Employer Identification No.)** |

---

#### 100 Technology Square

#### Sixth Floor

#### Cambridge, MA 02139

#### (Address of principal executive offices, including zip code)
(617) 914-8420

#### (Registrant's telephone number, including area code)

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **symbol(s)** | **Name of each exchange**<br> **on which registered** |
| **Common Stock, $0.0001 par value per share** | **AVRO** | **Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

As previously disclosed, on October 4, 2022, AVROBIO, Inc. (the "Company") received a written notice from the staff (the "Staff") of the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), notifying the Company that, for the 30 consecutive business day period between August 22, 2022 through October 3, 2022, the Company's common stock, $0.0001 par value per share (the "Common Stock"), had not maintained a minimum bid price of $1.00 per share, required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement").

On February 23, 2023, the Company received a written notice from the Staff notifying the Company that for 10 consecutive business days, from February 8, 2023 to February 22, 2023, the closing bid price for the Company's Common Stock was at $1.00 per share or greater. Accordingly, the Staff has advised that the Company has regained compliance with the Minimum Bid Price Requirement and indicated that the matter is now closed.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | AVROBIO, INC. | AVROBIO, INC. |
| Date: February 27, 2023 | By: | /s/ Geoff MacKay |
|  |  | Geoff MacKay |
|  |  | President and Chief Executive Officer |

---

------